A pilot study of the PD-1 targeting agent AMP-224 combined with low-dose cyclophosphamide and stereotactic body radiation therapy in patients with metastatic colorectal cancer

This study aimed to investigate the benefit of combining immunotherapy (AMP-224) with radiation for patients with metastatic colorectal cancer. Fifteen patients were enrolled. No objective response was observed though 20% patients had stable disease. Signal of immune modulation was noted.

Saved in:
Bibliographic Details
Published in:Clinical colorectal cancer 2019-07, Vol.18 (4), p.e349-e360
Main Authors: Floudas, Charalampos S., Brar, Gagandeep, Mabry-Hrones, Donna, Duffy, Austin G., Wood, Bradford, Levy, Elliot, Krishnasamy, Venkatesh, Fioravanti, Suzanne, Bonilla, Cecilia M., Walker, Melissa, Morelli, Maria Pia, Kleiner, David E., Steinberg, Seth M., Figg, William D., Greten, Tim F., Xie, Changqing
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study aimed to investigate the benefit of combining immunotherapy (AMP-224) with radiation for patients with metastatic colorectal cancer. Fifteen patients were enrolled. No objective response was observed though 20% patients had stable disease. Signal of immune modulation was noted.
ISSN:1533-0028
1938-0674
DOI:10.1016/j.clcc.2019.06.004